Detalles de la búsqueda
1.
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Cancer Sci
; 115(4): 1296-1305, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402853
2.
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Br J Cancer
; 130(10): 1679-1686, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575731
3.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469185
4.
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(2): 190-199, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33824476
5.
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Jpn J Clin Oncol
; 51(8): 1261-1268, 2021 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34037224
6.
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(3): 465, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34079081
7.
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.
Clin Cancer Res
; 29(10): 1879-1886, 2023 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36971777
8.
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 9(9): 1260-1266, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37270698
9.
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.
Cell Rep Med
; 4(11): 101280, 2023 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37944528
10.
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Clin Cancer Res
; 28(6): 1117-1126, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34789481
11.
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Lancet Respir Med
; 8(11): 1132-1143, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32479794
12.
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 26(6): 1237-1246, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31822497
13.
Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 22(13): 3192-200, 2016 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26839144
Resultados
1 -
13
de 13
1
Próxima >
>>